With regard to fetuin-A, many clinical trials have been conducted to evaluate the therapeutic effect of metformin in NAFLD and have shown that it reduces serum fetuin-A levels in patients with NAFLD/MASLD, although this reduction was not associated with corresponding histologic improvements in the liver [87]. The gene discussed is AHSG; the disease is metabolic dysfunction-associated steatotic liver disease.